Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DNA XSONM -6.88%35 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates SONM with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 670 Capital Markets companies, DNA X ranks better than 67.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. DNA X's EBITDA for the
three
months ended in Mar. 2026 was $-3.80 Mil. DNA X's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, DNA X's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DNA X EBITDA Margin % Related Terms
DNA X EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DNA X's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SONM vs CETX, OLB, BRQSF: EBITDA Margin % Comparison
For the Capital Markets subindustry, DNA X's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DNA X EBITDA Margin % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, DNA X's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DNA X's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNA X (SONM) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DNA X and its competitors. According to the industry distribution chart, DNA X ranks #220 out of 670 companies in the Capital Markets industry, placing it in the top 32.8%.
Is DNA X's EBITDA Margin % too high?
DNA X's current EBITDA Margin % is 0.00%. Based on the distribution chart, DNA X ranks #220 out of 670 companies in the Capital Markets industry, which is above the industry midpoint. Overall, DNA X has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does DNA X's EBITDA Margin % compare to CETX and OLB?
According to the Capital Markets industry distribution chart, DNA X ranks #220 out of 670 companies for EBITDA Margin %. This puts DNA X in the upper half of its industry. The industry median EBITDA Margin % is 22.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Capital Markets company?
The median EBITDA Margin % among Capital Markets companies is 22.08, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DNA X and its competitors. For the Capital Markets industry, the median EBITDA Margin % is 22.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DNA X's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DNA X stock overvalued right now?
DNA X (SONM) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. DNA X's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DNA X (SONM), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.
35GF Score
Get the complete analysis for SONM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SONM has been successfully added to your 
